These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23178365)

  • 21. Oncology nurses' knowledge, practice, and educational needs regarding cancer genetics.
    Peterson SK; Rieger PT; Marani SK; deMoor C; Gritz ER
    Am J Med Genet; 2001 Jan; 98(1):3-12. PubMed ID: 11426452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytogenetics and fluorescence in-situ hybridization in detection of hematological malignancies.
    Frenny VJ; Antonella Z; Luisa A; Shah AD; Sheth JJ; Rocchi M
    Indian J Cancer; 2003; 40(4):135-9. PubMed ID: 14716109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
    Stewart AK; Fonseca R
    J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tumor cytogenetics: between molecular genetics and clinical oncology].
    Rudolph G
    Dtsch Med Wochenschr; 1989 Aug; 114(33):1253-9. PubMed ID: 2670501
    [No Abstract]   [Full Text] [Related]  

  • 25. [Comparison of standard prognostic factors with the deletion of 13q14 detected by interphase fluorescence in situ hybridization on separated and unseparated bone marrow cells in multiple myeloma].
    Smejkalová J; Vranová V; Oltová A; Kuglík P; Filková H; Heinigová J; Kovárová L; Adam Z; Krejcí M; Pour L; Büchler T; Svobodník A; Vostrejsová S; Kalábová V; Vorlícek J; Penka M; Hájek R
    Cas Lek Cesk; 2005; 144(7):483-8. PubMed ID: 16161543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
    Avet-Loiseau H; Attal M; Campion L; Caillot D; Hulin C; Marit G; Stoppa AM; Voillat L; Wetterwald M; Pegourie B; Voog E; Tiab M; Banos A; Jaubert J; Bouscary D; Macro M; Kolb B; Traulle C; Mathiot C; Magrangeas F; Minvielle S; Facon T; Moreau P
    J Clin Oncol; 2012 Jun; 30(16):1949-52. PubMed ID: 22547600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma.
    Chiecchio L; Protheroe RK; Ibrahim AH; Cheung KL; Rudduck C; Dagrada GP; Cabanas ED; Parker T; Nightingale M; Wechalekar A; Orchard KH; Harrison CJ; Cross NC; Morgan GJ; Ross FM
    Leukemia; 2006 Sep; 20(9):1610-7. PubMed ID: 16826223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complex chromosome rearrangements and congenital anomalies.
    Kousseff BG; Nichols P; Essig YP; Miller K; Weiss A; Tedesco TA
    Am J Med Genet; 1987 Apr; 26(4):771-82. PubMed ID: 3591822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute myeloid leukemia with inv(16) with CBFB-MYH11, 3'CBFB deletion, variant t(9;22) with BCR-ABL1, and del(7)(q22q32) in a pediatric patient: case report and literature review.
    Tirado CA; Valdez F; Klesse L; Karandikar NJ; Uddin N; Arbini A; Fustino N; Collins R; Patel S; Smart RL; Garcia R; Doolittle J; Chen W
    Cancer Genet Cytogenet; 2010 Jul; 200(1):54-9. PubMed ID: 20513535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
    Jagannath S; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Cowan JM; Anderson KC
    Leukemia; 2007 Jan; 21(1):151-7. PubMed ID: 17096017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel chromosomal translocations in multiple myeloma: t(13;16)(q14;q24) and t(1;15)(q10;q26).
    Akalin I; Kutlay NY; Ilhan O; Tukun A
    Int J Lab Hematol; 2007 Jun; 29(3):215-20. PubMed ID: 17474900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
    Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytogenetics of extramedullary manifestations in multiple myeloma.
    Billecke L; Murga Penas EM; May AM; Engelhardt M; Nagler A; Leiba M; Schiby G; Kröger N; Zustin J; Marx A; Matschke J; Tiemann M; Goekkurt E; Heidtmann HH; Vettorazzi E; Dierlamm J; Bokemeyer C; Schilling G
    Br J Haematol; 2013 Apr; 161(1):87-94. PubMed ID: 23368088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH.
    Parry-Jones N; Matutes E; Morilla R; Brito-Babapulle V; Wotherspoon A; Swansbury GJ; Catovsky D
    Br J Haematol; 2007 Apr; 137(2):117-24. PubMed ID: 17391491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
    Klein U; Jauch A; Hielscher T; Hillengass J; Raab MS; Seckinger A; Hose D; Ho AD; Goldschmidt H; Neben K
    Cancer; 2011 May; 117(10):2136-44. PubMed ID: 21523726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cytogenetics of malignant lymphomas].
    Schlegelberger B
    Verh Dtsch Ges Pathol; 1992; 76():60-5. PubMed ID: 1283277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia.
    Freireich EJ; Cork A; Stass SA; McCredie KB; Keating MJ; Estey EH; Kantarjian HM; Trujillo JM
    Leukemia; 1992 Jun; 6(6):500-6. PubMed ID: 1602788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.
    Nagy Z; Kajtár B; Jáksó P; Dávid M; Kosztolányi S; Hermesz J; Kereskai L; Pajor L; Alpár D
    Leuk Res; 2011 Aug; 35(8):1114-6. PubMed ID: 21377730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An 800-kb region of deletion at 13q14 in human prostate and other carcinomas.
    Chen C; Frierson HF; Haggerty PF; Theodorescu D; Gregory CW; Dong JT
    Genomics; 2001 Oct; 77(3):135-44. PubMed ID: 11597138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.